Stock listing
KRX:006280 GC Biopharma Corp. (녹십자) 주가
Follow GC Biopharma Corp. into a list and get an email when it puts out news.
Share price · KRX:006280
₩130,000 KRW -800 (-0.6%)
Close on Nov 20, 2026
- Day range
- ₩129,500 – ₩135,000 KRWNov 20, 2026
- Volume
- 21,215 sharesNov 20, 2026
- Market cap
- ₩1.48T KRWAt the close on Nov 20, 2026 · price × 11.41M shares outstanding
- 52-week range
- ₩105,900 – ₩183,800 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩3.29B KRWMedian day 19,758 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:006280 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩130,000 | -800 | -0.6% | ₩131,400 | ₩135,000 | ₩129,500 | 21,215 | |
| ₩130,800 | -4,200 | -3.1% | ₩133,200 | ₩134,250 | ₩129,500 | 23,875 | |
| ₩135,000 | +1,800 | +1.4% | ₩132,900 | ₩136,800 | ₩132,300 | 28,218 | |
| ₩133,200 | -800 | -0.6% | ₩134,000 | ₩135,500 | ₩132,200 | 17,488 | |
| ₩134,000 | -6,000 | -4.3% | ₩136,400 | ₩136,800 | ₩133,000 | 22,334 | |
| ₩140,000 | +1,800 | +1.3% | ₩138,100 | ₩140,000 | ₩133,900 | 48,590 | |
| ₩138,200 | +800 | +0.6% | ₩137,400 | ₩141,000 | ₩135,100 | 22,721 | |
| ₩137,400 | +700 | +0.5% | ₩138,000 | ₩139,300 | ₩136,100 | 31,316 | |
| ₩136,700 | -3,400 | -2.4% | ₩140,500 | ₩140,800 | ₩136,200 | 21,316 | |
| ₩140,100 | -2,200 | -1.5% | ₩138,500 | ₩144,000 | ₩135,500 | 49,828 | |
| ₩142,300 | +3,700 | +2.7% | ₩140,100 | ₩145,400 | ₩140,000 | 60,543 | |
| ₩138,600 | +2,300 | +1.7% | ₩136,100 | ₩139,000 | ₩134,100 | 44,684 | |
| ₩136,300 | +2,400 | +1.8% | ₩132,800 | ₩139,800 | ₩132,600 | 62,229 | |
| ₩133,900 | +3,700 | +2.8% | ₩128,100 | ₩135,000 | ₩128,100 | 30,440 | |
| ₩130,200 | -1,800 | -1.4% | ₩133,100 | ₩133,400 | ₩128,100 | 25,903 | |
| ₩132,000 | +1,500 | +1.1% | ₩130,100 | ₩132,000 | ₩129,600 | 14,411 | |
| ₩130,500 | +1,400 | +1.1% | ₩129,100 | ₩132,700 | ₩129,000 | 12,863 | |
| ₩129,100 | -500 | -0.4% | ₩129,700 | ₩131,300 | ₩128,400 | 16,808 | |
| ₩129,600 | -2,600 | -2.0% | ₩130,700 | ₩132,900 | ₩128,600 | 14,259 | |
| ₩132,200 | +1,200 | +0.9% | ₩130,900 | ₩133,500 | ₩129,100 | 28,926 | |
| ₩131,000 | -400 | -0.3% | ₩130,200 | ₩133,000 | ₩128,800 | 20,320 | |
| ₩131,400 | -1,300 | -1.0% | ₩133,300 | ₩137,500 | ₩130,700 | 28,919 | |
| ₩132,700 | +2,000 | +1.5% | ₩129,300 | ₩134,400 | ₩128,600 | 29,031 | |
| ₩130,700 | +3,100 | +2.4% | ₩127,500 | ₩130,900 | ₩126,600 | 18,750 | |
| ₩127,600 | +2,600 | +2.1% | ₩126,500 | ₩130,600 | ₩125,500 | 20,186 | |
| ₩125,000 | -2,400 | -1.9% | ₩127,900 | ₩130,800 | ₩123,100 | 15,487 | |
| ₩127,400 | 0 | 0.0% | ₩126,800 | ₩130,300 | ₩125,800 | 15,944 | |
| ₩127,400 | -700 | -0.5% | ₩127,200 | ₩127,500 | ₩123,200 | 18,861 | |
| ₩128,100 | -1,300 | -1.0% | ₩129,200 | ₩130,700 | ₩127,000 | 15,883 | |
| ₩129,400 | -1,100 | -0.8% | ₩130,500 | ₩130,500 | ₩127,900 | 30,053 | |
| ₩130,500 | +3,000 | +2.4% | ₩129,200 | ₩131,000 | ₩127,700 | 26,923 | |
| ₩127,500 | +1,700 | +1.4% | ₩126,500 | ₩130,500 | ₩126,400 | 22,805 | |
| ₩125,800 | -3,500 | -2.7% | ₩129,100 | ₩129,800 | ₩124,300 | 14,875 | |
| ₩129,300 | +6,300 | +5.1% | ₩124,400 | ₩129,600 | ₩123,400 | 33,177 | |
| ₩123,000 | -200 | -0.2% | ₩123,800 | ₩124,700 | ₩121,300 | 21,185 | |
| ₩123,200 | 0 | 0.0% | ₩124,300 | ₩124,600 | ₩121,400 | 12,951 | |
| ₩123,200 | -100 | -0.1% | ₩123,400 | ₩124,800 | ₩122,600 | 12,578 | |
| ₩123,300 | 0 | 0.0% | ₩123,800 | ₩125,400 | ₩123,100 | 14,262 | |
| ₩123,300 | -2,400 | -1.9% | ₩125,700 | ₩126,300 | ₩123,100 | 18,851 | |
| ₩125,700 | +3,300 | +2.7% | ₩122,000 | ₩126,500 | ₩121,900 | 18,164 | |
| ₩122,400 | -300 | -0.2% | ₩124,200 | ₩124,200 | ₩120,700 | 117,126 | |
| ₩122,700 | +300 | +0.2% | ₩123,600 | ₩124,200 | ₩122,000 | 12,744 | |
| ₩122,400 | -2,500 | -2.0% | ₩126,000 | ₩126,300 | ₩121,600 | 17,432 | |
| ₩124,900 | -1,700 | -1.3% | ₩126,300 | ₩127,400 | ₩124,800 | 15,789 | |
| ₩126,600 | -1,700 | -1.3% | ₩127,100 | ₩128,000 | ₩124,800 | 15,217 | |
| ₩128,300 | -1,800 | -1.4% | ₩128,300 | ₩131,100 | ₩127,200 | 20,355 | |
| ₩130,100 | +2,700 | +2.1% | ₩126,100 | ₩130,100 | ₩125,400 | 26,875 | |
| ₩127,400 | +400 | +0.3% | ₩127,000 | ₩127,700 | ₩126,100 | 15,358 | |
| ₩127,000 | -300 | -0.2% | ₩128,400 | ₩128,500 | ₩126,100 | 17,150 | |
| ₩127,300 | -300 | -0.2% | ₩128,800 | ₩128,800 | ₩125,700 | 13,558 | |
| ₩127,600 | +600 | +0.5% | ₩128,200 | ₩128,800 | ₩125,500 | 9,199 | |
| ₩127,000 | 0 | 0.0% | ₩127,900 | ₩131,300 | ₩125,700 | 17,766 | |
| ₩127,000 | -1,100 | -0.9% | ₩127,800 | ₩131,900 | ₩126,700 | 19,181 | |
| ₩128,100 | -1,000 | -0.8% | ₩127,900 | ₩129,300 | ₩127,200 | 13,517 | |
| ₩129,100 | -1,400 | -1.1% | ₩128,900 | ₩129,300 | ₩125,700 | 17,348 | |
| ₩130,500 | +3,400 | +2.7% | ₩126,300 | ₩130,600 | ₩125,500 | 18,676 | |
| ₩127,100 | -3,400 | -2.6% | ₩130,600 | ₩130,900 | ₩126,200 | 15,160 | |
| ₩130,500 | +4,200 | +3.3% | ₩129,100 | ₩131,000 | ₩127,100 | 19,330 | |
| ₩126,300 | -4,000 | -3.1% | ₩127,600 | ₩129,500 | ₩124,000 | 21,796 | |
| ₩130,300 | +8,200 | +6.7% | ₩124,900 | ₩131,100 | ₩124,200 | 41,331 | |
| ₩122,100 | -3,300 | -2.6% | ₩122,800 | ₩123,700 | ₩120,000 | 29,371 | |
| ₩125,400 | +4,400 | +3.6% | ₩133,500 | ₩133,800 | ₩123,700 | 65,683 |
Splits
1 split · KRX:006280 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split |
- Ticker
- KRX:006280
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Aug 24, 2026
GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
Latest news
GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
Aug 24, 2026
Closed ₩130,300 (+6.7%) on Aug 24, 2026
GC Biopharma Announces Lunch Symposium and Poster Presentations on IVIG Product Characterization at the 2026 CIS Annual Meeting
May 4, 2026
Closed ₩135,800 (-1.2%) on May 6, 2026
GC Biopharma Announces Presentation on Aggregation Profiles of Commercial IVIG Products at NHIA 2026
Apr 16, 2026
Closed ₩151,200 (+1.1%) on Apr 17, 2026
GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
Apr 6, 2026
Closed ₩140,000 (-0.4%) on Apr 6, 2026
GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala
Mar 26, 2026
Closed ₩148,300 (-0.5%) on Mar 26, 2026
GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
Mar 11, 2026
Closed ₩151,400 (-0.1%) on Mar 11, 2026
GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
Dec 22, 2025
Closed ₩159,700 (-2.7%) on Dec 23, 2025
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
Dec 8, 2025
Closed ₩133,100 (-1.7%) on Dec 8, 2025
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
Dec 2, 2025
Closed ₩137,500 (+0.2%) on Dec 2, 2025
GC Biopharma Corp. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 9 in the last 12 months · 23 in all · newest Aug 24, 2026 · oldest 2025
- Decks
- 3 decks · latest Jan 31, 2024
Valuation
EV/sales 0.9× against a median of 3.8×: the lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩1.75T KRW
- P/E
- Loss
- EV/sales
- 0.9×
- EV/EBITDA
- 13.2×
- Price/book
- 1.2×
- Gross margin
- 26.4%
- Operating margin
- 2.4%
- Net margin
- −2.5%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GC Biopharma Corp. · KRX:006280 | US$1.10B | US$1.30B | n/a | 0.9× | 13.2× | 1.2× | −2.5% | 0.3× | n/a |
| Hualan Biological Vaccine Inc. Class A · SZSE:301207 | US$1.16B | US$845.9M | 167× | 8.1× | n/a | 1.5× | 6.6% | 0.0× | n/a |
| Chongqing Lummy Pharmaceutical Co., Ltd. Class A · SZSE:300006 | US$1.15B | US$1.04B | n/a | 9.6× | n/a | 4.5× | −16.6% | 0.1× | n/a |
| Idorsia Ltd. · SIX:IDIA | US$1.15B | US$2.66B | n/a | 10.2× | n/a | n/a | −128.8% | n/a | n/a |
| Harrow, Inc. · NASDAQ:HROW | US$1.14B | US$1.36B | n/a | 4.5× | 188× | 39.1× | −9.4% | 10.0× | 1.31 |
| Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550 | US$1.12B | US$929.9M | 32.3× | 4.1× | n/a | 2.7× | 15.3% | 0.0× | n/a |
| Vetoquinol SA · EURONEXT:VETO | US$1.09B | US$848.6M | 17.4× | 1.5× | 7.0× | 1.6× | 10.9% | 0.0× | n/a |
| North China Pharmaceutical Company Ltd. Class A · SSE:600812 | US$1.09B | US$1.55B | 81.1× | 1.3× | n/a | 1.3× | 1.1% | 0.8× | n/a |
| Basilea Pharmaceutica AG · SIX:BSLN | US$1.07B | US$964.2M | 22.4× | 3.5× | 15.2× | 5.6× | 17.3% | 0.5× | n/a |
| Tianjin Ringpu Bio-technology Co., Ltd. Class A · SZSE:300119 | US$1.06B | US$873.7M | 21.0× | 1.6× | n/a | 1.5× | 9.6% | 0.1× | n/a |
| Beijing Foyou Pharma Co., Ltd. Class A · SSE:601089 | US$1.03B | US$710.8M | 18.7× | 1.3× | n/a | 1.8× | 10.2% | 0.0× | n/a |
| Median of the others | US$1.11B | US$947.1M | 22.4× | 3.8× | 15.2× | 1.8× | 8.1% | 0.1× | 1.31 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 192250.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- 17290.16 · 4 analysts
- Revenue, year to Dec 2026
- 1.9T · 3 analysts
Events
- Next results
- Jan 25, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 16, 2026 · Before open | −0.6% |
| Q2 2026 | Aug 14, 2026 · Before open | −0.2% |
| Q1 2026 | May 15, 2026 · Before open | −4.2% |
| Q4 2025 | Mar 18, 2026 | −2.1% |
| Q3 2025 | Nov 14, 2025 · Before open | +0.1% |
| Q2 2025 | Aug 14, 2025 · Before open | −0.6% |
| Q1 2025 | May 15, 2025 · Before open | +2.5% |
| Q4 2024 | Mar 18, 2025 | +4.0% |
| Q3 2024 | Oct 30, 2024 · After close | +1.8% |
| Q2 2024 | Aug 5, 2024 · After close | +10.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | −1.9% |
| Q4 2023 | Jan 31, 2024 · After close | +1.7% |
| Q3 2023 | Nov 1, 2023 · After close | +1.2% |
| Q2 2023 | Aug 1, 2023 · After close | −0.4% |
| Q1 2023 | May 2, 2023 · After close | −1.9% |
| Q4 2022 | Feb 14, 2023 · After close | −4.6% |
| Q3 2022 | Nov 1, 2022 · After close | +3.1% |
| Q2 2022 | Aug 1, 2022 · After close | −1.8% |
| Q1 2022 | May 2, 2022 · After close | −3.1% |
| Q4 2021 | Feb 14, 2022 · After close | −7.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (January 2024) | Investor day | 14 slides | Jan 31, 2024 |
| Investor Day (January 2024) | Investor day | 13 slides | Jan 31, 2024 |
| FY2023 Earnings Presentation | Earnings | 5 slides | Jan 31, 2024 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.99T | 1.68T | 1.63T | 1.71T | 1.54T | 1.50T | 1.37T | 1.33T | 1.29T | 1.20T |
| Cost of revenue | 1.44T | 1.20T | 1.14T | 1.13T | 1.02T | 1.06T | 997.4B | 989.0B | 921.1B | 845.8B |
| Gross profit | 554.1B | 481.9B | 484.6B | 581.8B | 520.6B | 440.6B | 372.3B | 345.9B | 366.8B | 352.1B |
| Research and development | 152.9B | 166.2B | 173.5B | 191.3B | 146.0B | 138.0B | 126.7B | 122.0B | 108.6B | 112.3B |
| Selling, general and administrative | 166.3B | 130.1B | 134.4B | 165.1B | 169.1B | 145.2B | 112.3B | 92.2B | 84.4B | 82.3B |
| Operating income | 69.1B | 32.1B | 34.4B | 81.3B | 73.7B | 50.3B | 40.3B | 50.2B | 90.3B | 78.5B |
| Depreciation and amortization | 87.7B | 81.0B | 75.9B | 65.1B | 55.9B | 48.8B | 46.7B | 40.1B | 36.7B | 31.1B |
| EBITDA | 156.8B | 113.1B | 110.3B | 146.4B | 129.6B | 99.1B | 87.0B | 90.4B | 127.0B | 109.5B |
| Interest expense | 50.3B | 40.4B | 28.5B | 18.4B | 12.5B | 10.4B | 9.61B | 7.61B | 0 | 0 |
| Income before tax | -35.3B | -41.1B | -27.1B | 85.7B | 172.6B | 104.5B | -6.14B | 50.2B | 72.2B | 79.5B |
| Income tax | 35.6B | 15.4B | 5.15B | 15.9B | 15.4B | 14.4B | ||||
| Net income | -4.67B | -26.3B | -26.6B | 65.5B | 123.2B | 81.0B | -3.64B | 34.4B | 53.2B | 63.0B |
| Earnings per share, basic | -409.51 | -2,302.62 | -2,333.42 | 5,734.87 | 10,795.57 | 7,101.34 | -318.72 | 3,016.64 | 4,665.36 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 49.4B | 22.6B | 49.7B | 105.4B | 186.1B | 232.3B | 98.5B | 96.6B | 171.0B | 56.9B |
| Short-term investments | 1.43B | 1.43B | 5.80B | 6.94B | 16.9B | 23.2B | 43.1B | 10.1B | 268.0M | 60.3B |
| Receivables | 402.7B | 386.5B | 437.0B | 394.2B | 413.8B | 402.1B | 405.2B | 391.2B | 368.2B | 345.0B |
| Inventory | 891.6B | 746.6B | 516.2B | 442.4B | 455.0B | 437.1B | 406.6B | 386.9B | 381.3B | 320.8B |
| Current assets | 1.37T | 1.20T | 1.04T | 980.4B | 1.09T | 1.13T | 961.8B | 893.4B | 926.5B | 801.4B |
| Property, plant and equipment | 899.8B | 751.1B | 718.7B | 559.7B | 552.0B | 554.0B | ||||
| Goodwill | 118.1B | 125.6B | 142.5B | 142.5B | 142.5B | 10.1B | 10.1B | 10.2B | 15.1B | 17.8B |
| Total assets | 2.97T | 2.74T | 2.64T | 2.53T | 2.46T | 2.15T | 1.96T | 1.72T | 1.70T | 1.55T |
| Accounts payable | 177.3B | 156.8B | 143.8B | 121.3B | 119.5B | 134.8B | 139.3B | 144.9B | 158.8B | 118.3B |
| Current liabilities | 1.15T | 769.5B | 868.9B | 540.7B | 552.9B | 589.4B | 401.4B | 303.5B | 260.1B | 303.3B |
| Long-term debt | 253.5B | 339.5B | 84.9B | 278.8B | 280.3B | 194.2B | 272.1B | 263.3B | 307.0B | 149.5B |
| Total liabilities | 1.58T | 1.26T | 1.10T | 958.9B | 962.4B | 882.1B | 775.2B | 597.2B | 594.9B | 491.6B |
| Shareholders' equity | 1.22T | 1.25T | 1.30T | 1.33T | 1.27T | 1.12T | 1.05T | 1.06T | 1.04T | 993.1B |
| Shares outstanding | 11.4M | 11.4M | 11.4M | 11.4M | 11.4M | 11.4M | 11.4M | 11.4M | 11.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 99.5B | -53.5B | -5.47B | 119.2B | 126.0B | 36.0B | 40.3B | 14.4B | 57.9B | -1.74B |
| Capital spending | -105.3B | -42.4B | -126.0B | -94.7B | -102.3B | -82.9B | -127.5B | -41.4B | -29.5B | -98.7B |
| Free cash flow | -5.82B | -95.9B | -131.5B | 24.5B | 2.44B | -65.4B | -107.3B | -50.6B | 2.31B | -100.4B |
| Cash from investing | -132.1B | 29.7B | -177.9B | -86.1B | 14.8B | -111.1B | ||||
| Cash from financing | -41.3B | 81.0B | 140.8B | -4.51B | 48.2B | 110.6B | ||||
| Dividends paid | -18.8B | -19.5B | -24.8B | -24.0B | -18.5B | -12.7B | -12.4B | -15.3B | -15.3B | -20.5B |
| Share buybacks | -21.8B | |||||||||
| Change in cash | 26.8B | -27.1B | -55.7B | -80.7B | -46.2B | 133.8B | 1.83B | -74.3B | 114.1B | -816.1M |
Cap table
Built by 6ix from GC Biopharma Corp.’s releases
- Common shares
- 11,413,127
- Fully diluted
- 11,413,127
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 11,413,127 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,413,127 |
Log in to ask 6ix AI your own questions about GC Biopharma Corp.